Substances for treatment of coronavirus infection
AssigneeScandibio Therapeutics AB
InventorsAdil Mardinoglu, Jan Borén, Mathias Uhlén
Life of this patent
Estimating the term…
Abstract
There is provided a method of treating a human subject that is or has been infected with a coronavirus, comprising administration to the subject of: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate.
Claims20
A method of treating a human subject that is or has been infected with a coronavirus, comprising administration to the subject of:
- A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine;
- B) N-acetyl cysteine, cysteine and/or cystine;
- C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine;
- and
- D) nicotinamide riboside, quinolinate, deamino-NAD-+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate;
- thereby treating the human subject;
- wherein the subject does not have non-alcoholic fatty liver disease.
A method of treating a human subject suffering from a severe acute respiratory syndrome (SARS), comprising administration to the subject of:
- A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine;
- B) N-acetyl cysteine, cysteine and/or cystine;
- C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylaminoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine;
- and
- D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate;
- thereby treating the SARS;
- wherein the subject does not have non-alcoholic fatty liver disease.
Dependencies are inferred from the claim text.